The Pfizer and Johnson & Johnson-backed cancer treatment developer is eyeing expansion in Asia after receiving $40m in additional series D funding.
US-based oncology therapy technology developer Reflexion secured $40m on Tuesday from healthcare-focused investment firm Ally Bridge Group to expand a series D round featuring pharmaceutical firms Pfizer and Johnson & Johnson to $150m. The company said it raised $110m of series D funding across 2020, including $100m from investors including Pfizer Ventures and Johnson &…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.